NeoImmuneTech, Inc.

NeoImmuneTech, Inc. is a clinical-stage T cell-based biotechnology company that develops and sells immuno-therapeutics in Korea. Its pipeline includes NT-I7, an IL-7 class T cell amplifier for acute radiation syndrome, and a Heterodimer hybrid Fc antibody platform technology, along with NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.